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The aim of this study was to develop and validate a UV spectrophotometric method for determination of 
LPSF/AC04 from inclusion complex and encapsulated into liposomes. The validation parameters were 
determined according to the International Conference on Harmonisation (ICH) and National Health 
Surveillance Agency (ANVISA) guidelines. LPSF/AC04 was determined at 250 nm in methanol by a UV 
spectrophotometric method, exhibiting linearity in the range from 0.3 to 2 µg.mL−1 (Absorbance=0.18068 
x [LPSF/AC04 µg.mL-1] + 0.00348), (r2=0.9995). The limits of detection and quantification were  
0.047µg.mL−1 and 0.143µg.mL−1, respectively. The method was accurate, precise, reproducible and robust 
since all the samples analyzed had coefficient of variation of less than 5% and no statistically significant 
difference between theoretical and practical concentrations was detected. Thus, a rapid, simple, low cost 
and sensitive spectrophotometric method was developed and validated for determining the content of 
inclusion complex and liposomes containing LPSF/AC04.
Uniterms: UV Spectrophotometry/quantitative analysis/method validation. Acridine derivatives/
determination. Inclusion complex. Liposomes.
O objetivo deste estudo foi desenvolver e validar um método espectrofotométrico para determinação do 
LPSF/AC04 em complexo de inclusão e encapsulado em lipossomas. Os parâmetros de validação foram 
determinados de acordo com o International Conference on Harmonisation (ICH) e Agência Nacional 
de Vigilância Sanitária (ANVISA). OLPSF/AC04 foi determinado a 250 nm em metanol pelo método 
espectrofotométrico UV, que apresenta linearidade na faixa de 0,3 a 2 µg/mL (Absorbância = 0,18068 x 
[LPSF/AC04 µg/mL] + 0,00348), (r2 = 0,9995). Os limites de detecção e quantificação foi 0,047 µg/mL 
e 0,143 µg/mL, respectivamente. O método foi exato, preciso, reprodutível e robusto e todas as amostras 
analisadas apresentaram coeficiente de variação menor que 5% e não houve diferença estatisticamente 
significante entre a concentração teórica e a prática. Assim, um método espectrofotométrico rápido, 
simples, sensível e de baixo custo foi desenvolvido e validado para determinar o conteúdo do LPSF/
AC04 em complexos de inclusão e encapsulados em lipossomas.
Unitermos: Espectrofotometria UV/análise quantitativa/validação de método. Derivados acridínicos/
determinação. Complexos de inclusão. Lipossomas.
R. S. Ferraz, E. A. M. Mendonça, J. P. A. Silva, I. M. F. Cavalcanti, M. C. B. Lira-Nogueira, S. L. Galdino, I. R. Pitta, M. C. A. Lima, N. S. Santos-Magalhães184
INTRODUCTION
LPSF/AC04 (5Z)-[5-acridine-9-yl-methylene-3-
(4-methyl-benzyl)-thiazolidine-2,4-dione] (Figure 1A) 
is an acridinylidene thiazolidinedione, a monoacridinine 
structural analogue of amsacrine (Figure 1B) (Denny, 
2002; Mourão et al., 2005). A variety of different acridine 
derivatives has been synthesized and promising results 
obtained in some cases, prompting the development of 
new acridine-based drugs that present a wide spectrum of 
biological activities, such as antibacterial, antimalarial, 
antitrypanosomial (Bonse et al., 1999), antileishmanial 
and antiviral (Goodell et al., 2006) actions, and most 
notably antitumor activity (Goodell et al., 2008).
The rational design of drugs is one of the most useful 
approaches for the introduction of new drugs in therapy and 
widely used by researchers in the medicinal chemistry field. 
In this context, LPSF/AC04 is an acridine-based derivative, 
part of a series of new anticancer agents synthesized for 
the purpose of developing more effective and less toxic 
anticancer drugs. This molecule, with potential antitumor 
activity, was synthesized at the Laboratory of Rational 
Design and Synthesis of Drugs (LPSF) of the Federal 
University of Pernambuco, Brazil. LPSF/AC04 has 
shown antitumor activity with tumor inhibition of more 
than 85% in a murine sarcoma 180 model after 8 days of 
treatment with 100 mg/kg i.p/day (De Lima, Lins, Pitta, 
2007). In addition, a recent study has reported preliminary 
pharmacokinetics of LPSF/AC04 with a half-life of 
66 h and accumulation in different tissues (Pigatto et 
al., 2011). However, heterocyclic acridine derivatives 
such as LPSF/AC04 are characterized by low solubility 
in aqueous solutions, limiting both clinical trials and its 
therapeutic use.
In order to minimize this problem, incorporation 
of the drug into controlled release systems is required. 
Liposomes are widely used in pharmaceutical applications, 
such as for drug delivery vehicles of several therapeutic 
agents, given their versatility and clinical efficacy 
(Torchilin, 2006). In addition, cyclodextrins are used 
to improve the solubility of poorly hydrophilic drugs. 
Cyclodextrins (CyDs) have a relatively nonpolar 
cylindrical cavity that can bind, and thereby solubilize, 
a wide range of hydrophobic molecules (Loftsson, 
Hreinsdóttir, Másson, 2005; Loftsson, Duchêne, 2007). 
The main purpose of inclusion complex-loaded liposomes 
is to combine the advantages of cyclodextrins as drug 
solubility enhancement agents with those of liposomes 
as drug-targeting agents. Some authors have cited the use 
of cyclodextrins in the formation of inclusion complexes 
with hydrophobic drugs, including acridine derivatives, to 
enhance their solubility (Schuette et al., 1991; Correia et 
al., 2002; Loftsson, Hreinsdóttir, Másson, 2005; Loftsson, 
Duchêne, 2007; Mishur et al., 2011; Al Omari et al., 2011).
The quality control of pure drugs and dosage 
forms are carried out using official and validated 
methods. Despite the clear advantages of using the HPLC 
chromatographic technique, the method has several 
limitations such as the high cost of instrumentation and 
operation, relatively long analysis times and the need for 
experience in handling the equipment and in processing 
samples (Siqueira-Moura et al., 2008). Spectrophotometry 
is a highly convenient analytical technique that is widely 
used in laboratories for quality control given its simplicity, 
low cost and wide availability (Darwish et al., 2009).
The main objective of this work was to develop 
and validate a simple, precise, accurate and economical 
analytical method for quantifying LPSF/AC04 by UV-
spectrophotometry. Subsequently, the resultant method 
can be applied to determine pure drug and dosage forms, 
such as liposomes and inclusion complexes containing 
LPSF/AC04.
MATERIAL AND METHODS
Apparatus
A UV spectrophotometer (Ultrospec 3000 Pro, 
Amersham Pharmacia Biotech, Sweden) equipped 
with 10 mm quartz cells was used for all the absorption 
measurements. A magnetic stirrer (Variomag, Germany), 
Vibra Cell sonicator (Branson, USA), lyophilizer EZ-DRY 
(FTS Systems, USA) and thermostatically-controlled 
water bath (Bioblock Scientific, France) were employed.
Material and reagents
LPSF/AC04, obtained by the synthetic route 
N
S
NO
O
CH3
N
HN
MeO NHSO2Me
(A) (B)
FIGURE 1 - Chemical structures of (5-(acridine-9-yl-
methylene)-(4-methyl-benzyl)-thiazolidine-2,4-dione) – LPSF/
AC04 (A) and amsacrine (B).
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(Pitta e t  al . ,  2007), was kindly provided by the 
Laboratory of Medicinal Chemistry of the Federal 
University of Pernambuco, Brazil, CAS:440367-56-6. 
Cholesterol (CHOL), trehalose, stearylamine (SA) and 
2-hydroxypropyl-β-cyclodextrin (HP-β-CyD) were 
purchased from Sigma-Aldrich (St. Louis, USA); Soybean 
phosphatidylcholine (SPC, S100®) was obtained from 
Lipoid GmbH (Ludwigshafen, Germany). Methanol 
and chloroform (Merck, Darmstadt, Germany) were of 
analytical grade.
LPSF/AC04 standard solutions
LPSF/AC04 has a molecular weight of 410 and 
melting point of 199 °C, being characterized as a 
yellow-greenish amorphous powder. This molecule 
was characterized by spectroscopy (IR, 1H-NMR, 
Ms), C25H18N2O2S synthetic route has 96% yield: TLC 
benzene:ethyl acetate (9:1) Rf:0.45. IR cm-1(KBr): u 1746, 
1697, 1630, 1378, 1339, 1149, 758. 1H NMR (d ppm, 
CDCl3): 2.37 (s, CH3); 4.92 (s, CH2); 7.21 (d, 2H benzyl, 
J=7.8 Hz), 7.42 (d, 2H benzyl, J=8.1 Hz), 7.57-7.62 (m, 2H 
acridine), 7.8-7.85 (m,2H acridine), 7.96 (d, 2H acridine, 
J=7.8 Hz), 8.29 (d, 2H Benzyl J=8.1 Hz), 7.57-7.62 (m, 
2H acridine), 7.96 (d, 2H acridine, J=7.8 Hz), 8.29 (d, 2H 
acridine, J=8.7 Hz), 8.69 (s, 1H, CH). Ms, m/z (%):410 
(M 98.1), 411 (29.3), 305 (24.2), 235 (52.9), 190 (9), 105 
(100), 77 (8.3).
The s tandard  so lu t ions  of  LPSF/AC04 a t 
concentrations ranging from 0.3 to 2.0 µg.mL−1 were 
prepared in methanol from a stock solution (100 µg.mL−1). 
Standard solutions were prepared in triplicate to validate 
the analytical method.
Analytical method validation
The validation of the UV spectrophotometric 
analytical method was carried out based on parameters 
including linearity, limits of detection and quantification, 
specificity, precision, accuracy and robustness (ANVISA, 
2003; ICH, 1995A; ICH, 1996B). All assays were 
performed at 25 °C except for the robustness assay, where 
samples were also stored at 4 °C and 37 °C before analysis.
Initially, UV spectra of LPSF/AC04 at different 
concentrations (0.3, 0.5, 1, 1.5 and 2 mg.mL-1) were 
obtained to determine the wavelength of greatest 
absorptivity.
Specificity
The specificity of the method was evaluated by 
comparing the UV spectra of blank samples (HP-β-CD 
and unloaded liposomes) against LPSF/AC04 standard 
solution. The analysis of LPSF/AC04-loaded liposomes 
and LPSF/AC04:HP-β-CD inclusion complex scanning 
was also performed from 225 to 340 nm and checked for 
changes in absorbance at the respective wavelengths.
Linearity
The linearity of the proposed method was verified by 
preparing three different standard solutions of LPSF/AC04 
(0.3, 0.5, 1.0, 1.5 and 2.0 mg.mL-1), analyzed in triplicate, 
to plot nine derived analytical curves. The linearity of 
the analytical curve was evaluated by linear regression 
analysis using the least squares method and analysis of 
variance (ANOVA).
Limits of detection and quantification
Limits of detection (LOD) and quantification (LOQ) 
were estimated according to ICH guidelines (ICH, 1995A; 
ICH, 1995B). Limit of detection was calculated by: 
LOD = 3.3(σ/S), and limit of quantification was calculated 
by: LOQ = 10(σ/S), where σ is the standard deviation of 
the response of the blank and S is the slope of the analytical 
curve.
Accuracy
The accuracy of the method was determined by the 
recovery of a known amount of LPSF/AC04 added to 
samples of unloaded liposomes and HP-β-CD. Briefly, 
to determine the accuracy of the proposed method, 
different levels of drug concentrations were used: lower 
concentration (0.5 mg.mL-1), intermediate concentration 
(1.0 mg.mL-1) and higher concentration (1.5 mg.mL-1). 
A known aliquot of LPSF/AC04 stock solution was 
transferred to a 10mL volumetric flask containing unloaded 
liposomes or an accurately weighed amount of HP-β-CD 
equivalent to the quantity in the LPSF/AC04:HP-β-CD 
inclusion complex (Section 2.6.1) and filled to volume 
with methanol. A 1:10 dilution in methanol of the sample 
was then performed.
The samples were prepared in triplicate and analyzed 
by the proposed method. The relative standard deviation 
and LPSF/AC04 recovery percentage were employed to 
evaluate the accuracy of the method by applying equation 1. 
The paired t-test at a 95% level of significance was 
performed to compare the mean absorbance of the samples.
theoretical drug concentrationRecovery (%) = found drug concentration   Eq. 1
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Precision
Inter-day, intra-day and inter-analyst variations 
were studied to determine repeatability and intermediate 
precision of the proposed analytical method. Intermediate 
precision was determined by analyzing three different 
levels of LPSF/AC04 concentrations at 0.5, 1.0, 
1.5 mg.mL-1. Different solutions were prepared in triplicate 
by two different analysts at two different times during 
one day and analyzed for intra-day variations. The same 
procedure was followed for two different days to study 
inter-day and inter-analyst variations (ANVISA, 2003). 
The percentage relative standard deviation (%RSD) of the 
predicted concentrations from the regression equation was 
taken as the measure of precision. The paired t-test at a 
95% level of significance was performed to compare the 
mean absorbance of the samples.
Robustness
The robustness of the method was evaluated by 
changing the solvent suppliers and the temperature of the 
LPSF/AC04 samples (1.5 mg.mL1) at 4, 25 and 37 °C. 
The samples were previously prepared and transferred 
to sealed tubes and refrigerated at 4 °C or maintained at 
different temperatures (25 and 37 °C) for 24 h prior to 
analysis. Assays were performed three times under the 
same conditions (ANVISA, 2003; Ulu, Elmali, 2010).
Application of the method: determination of 
LPSF/AC04 from inclusion complex and liposomes
Preparation of LPSF/AC04:HP-b-CD inclusion complex
LPSF/AC-04:HP-β-CD complex was prepared using 
freeze-drying. First, stoichiometric amounts of HP-β-CD 
and LPSF/AC04 were dissolved in purified water and the 
mixture stirred for 72 h at 25 °C, then frozen in liquid 
nitrogen and finally lyophilized at 4x10-6 Bars for 72 h.
Preparation of LPSF/AC04 and LPSF/AC04:HP-b-CD-
loaded liposomes
LPSF/AC04 and LPSF/AC04:HP-β-CD-loaded 
liposomes were prepared using the thin lipid film method 
(Mendonça et al., 2012). Drug entrapment efficiency was 
determined using ultrafiltration by the ultracentrifugation 
technique (Ultrafree® units, Millipore, USA). Samples 
of LPSF/AC04 and LPSF/AC04:HP-β-CD-loaded 
liposomes (400 µL) were placed into the filtration unit 
and submitted to ultracentrifugation at 8,792g for 1 h. The 
samples were analyzed at 250 nm for determination of 
LPSF/AC04 content using a LPSF/AC04 analytical curve 
with concentrations ranging from 0.3 to 2.0 mg.mL-1. All 
samples were prepared in triplicate. Data are expressed 
as percentage of total content of LPSF/AC04 entrapped 
in liposomes.
RESULTS AND DISCUSSION
Analytical method validation
The absorption spectra of the LPSF/AC04 in 
methanol were recorded at concentrations ranging from 
0.3 to 2.0 μg.mL-1 (Figure 3). LPSF/AC04 was found 
to exhibit a maximum absorption peak (lmax) at 250 nm 
with a molar absorptivity (ε) of 7.60×104 L.mol−1.cm−1. In 
addition, no interference from the solvent in LPSF/AC04 
shoulder peaks near lmaxwas verified. Methanol can thus be 
considered a suitable solvent for validating the proposed 
method, since it showed no interference in the analysis, 
thus supporting the reproducibility of the results.
Specificity
The method described was specific for the 
determination of LPSF/AC04 in inclusion complex and 
liposomes. A well-defined peak of LPSF/AC04 was 
observed at 250 nm. In addition, the absorption spectrum 
of blank samples (HP-β-CD without LPSF/AC04) and 
unloaded liposomes showed no peak at the specific 
wavelength of LPSF/AC04 (Figure 3). The absorption 
peak of LPSF/AC04 at 250 nm was unchanged in the 
presence of the constituents of the liposomal formulation 
and HP-β-CD, thereby demonstrating the specificity of 
the method.
FIGURE 2 -  Scanning UV spectra of LPSF/AC04 at 
concentrations of 0.3, 0.5, 1, 1.5 and 2 μg mL-1 in methanol.
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TABLE I - Experimental results of validation parameters
Concentration 
(µg. mL -1)
Mean absorbance 
(± SD)a 
0.3 0.056 ± 0.002
0.5 0.095 ± 0.004
1.0 0.186 ± 0.007
1.5 0.271 ± 0.004
2.0 0.365 ± 0.007
aValues represent the mean of three analytical curves.
FIGURE 3 - Scanning UV spectra of: (A) LPSF/AC04 (1 μg.mL-1) (a); LPSF/AC04:HP-β-CD inclusion complexes (b) and HP-β-CD 
(c), (B) LPSF/AC04 (1 μg.mL-1) (a); unloaded liposomes (b) and LPSF/AC04-loaded liposomes 2 μg.mL-1) (c) diluted in methanol.
Linearity
Absorbance at lmax= 250 nm and concentrations of 
LPSF/AC04 ranging from 0.3 to 2.0 µg.mL-1 presented a 
linear relationship (Table I), and the regression analysis 
data are summarized in Table II. The analytical curves 
were fitted by least squares treatment to give the following 
mean regression equation: Absorbance = 0.18068 x [LPSF/
AC04, µg.mL−1] + 0.00348 (r2 = 0.9995, n=9) (Figure 4).
Limits of detection and quantification
The limit of detection (LOD) and the limit of 
quantification (LOQ) of LPSF/AC04 were 0.047 µg.mL-1 
and 0.143 µg.mL-1, respectively. These results showed 
that the method was sensitive even at low concentrations 
of LPSF/AC04.
Accuracy
The accuracy of the procedure was determined by 
recovery tests of known quantities of LPSF/AC04 (0.5, FIGURE 4 – Analytical curve or Plot linearity.
TABLE II - Optical characteristics of LPSF/AC04, statistical data 
of regression equations and validation parameters
LPSF/AC04 Validation Parameters
Optical characteristics
Molar absorptivity, ε (L.mol−1.cm−1) 7.60 × 104
Regression analysis
Slope (S.E.a) 0.18068 (2.09 x 10-3 )
Intercept (S.E.a) 0.00348 (2.58 x 10-3)
Regression coefficient (r2) 0.99946
Validation parameters
Measurement wavelength (nm) 250
Linear range (µg.mL-1) 0.3-2.0
Limit of detection, LOD (µg.mL-1) 0.047
Limit of quantification, LOQ (µg.mL-1) 0.143
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1.0 and 1.5 mg.mL-1) spiked in unloaded liposomes and 
HP-β-CD. LPSF/AC04 recoveries ranged from 101.06 
± 2.09% to 100.71 ± 1.35% for HP-β-CD (Table III) and 
99.36 ± 0.67% to 101.51 ± 1.91% (Table IV) for liposome. 
The mean LPSF/AC04 recovery values were close to 
100%, and their low standard deviation values evidence 
the high accuracy of the analytical method. These results 
reveal that small changes in the drug concentration in the 
solutions can be accurately determined by the proposed 
analytical method.
Precision
Repeatability (RSD%) ranged from 4.20 to 4.34 (%) 
for three levels of LPSF/AC04 concentrations (Table V). 
The results of repeatability (intra-day precision) of the 
method indicated the precision under the same operating 
conditions over a short period of time. Inter-day precision 
expresses within-laboratory variations on different days 
by different analysts (ANVISA, 2003). In the precision 
study, RSD% values were less than 5% in all cases and 
TABLE III - Recovery of LPSF/AC04 in HP-β-CD matrix to evaluate the accuracy of the UV method
Added Found  (±S.D.)a 
RSD 
(%)
Mean recovery % 
(±S.D.)a
t values
tcalb tcritb
0.5
1.0
1.5
0.505 ± 0.010
1.012 ± 0.028
1.510 ± 0.020
1.01
1.10
0.67
101.06 ± 2.09
101.26 ± 2.87
100.71 ± 1.35
0.47
0.52
0.45
4.30
4.30
4.30
aValues represent the mean of nine measurements. btcal is the calculated value and tcrit is the theoretical value based on the paired 
t-test at the level of significance of p = 0.05.
TABLE IV - Recovery of LPSF/AC04 in liposomes to assess the accuracy of the proposed method
Added Found  (±S.D.)a 
RSD 
(%)
Mean recovery% 
(±S.D.)a
t values
tcalb tcritb
0.5
1.0
1.5
0.502 ± 0.006 
1.015 ± 0.022 
1.490 ± 0.010
1.02
0.76
0.49
100.56 ±1.33 
101.51 ±1.91
99.36 ± 0.67
0.53
0.40
0.24
4.30
4.30
4.30
aValues represent the mean of nine measurements. btcal is the calculated value and tcrit is the theoretical value based on the paired 
t-test at the level of significance of p = 0.05.
TABLE V - Precision of proposed analytical method
Precision
[LPSF/AC04] 
Added 
(µg.mL-1)
[LPSF/AC04] 
Found ± S.D. 
(mg.mL-1)
R.S.D. 
(%) tcal
a  ttab b
Inter-day
Same analyst  
(days 1 and 2)
0.5 0.494 ± 0.02 4.36 0.57 2.57
1.0 1.011 ± 0.02 2.50 0.31 2.57
1.5 1.496 ± 0.02 1.52 0.73 2.57
Inter-day
Analysts 1 and 2  
(days 1 and 2)
0.5 0.498 ± 0.02 4.01 0.83 2.57
1.0 1.008 ± 0.05 4.78 0.68 2.57
1.5 1.529 ± 0.07 4.46 0.33 2.57
Intra-day
Different tests  
(same analyst; day 1)
0.5 0.494 ± 0.02 4.20 0.57 2.57
1.0 1.019 ± 0.04 4.34 0.32 2.57
1.5 1.534 ± 0.06 4.20 0.25 2.57
atcal is the calculated value; bttab is the theoretical value based on the paired t-test at the level of significance of p = 0.05 (n=6).
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TABLE VI - Robustness of the UV method using different solvent suppliers and temperatures of LPSF/AC04 samples
Parameters LPSF/AC04 (mg mL
-1)
Added Found ± S.D. RSD (%) tcala
Solvents 1 1.5 1.49 ± 0.01 0.93 0.62
Solvents 2 1.5 1.57 ± 0.01 1.07 0.01
4ºC 1.5 1.50 ± 0.06 4.13 0.84
25ºC 1.5 1.54 ± 0.01 1.07 0.05
37ºC 1.5 1.52 ± 0.00 2.33 0.42
atcal is the calculated value. The theoretical value tcrit = 4.30 is based on the paired t-test at the level of significance of p = 0.05 (n=3).
were well within the acceptable range, indicating that the 
method has good repeatability and inter-day precision 
(ANVISA, 2003).
Robustness
The analytical method proved to be robust (Table 
VI), since no statistically significant differences (Student´s 
t-test) were found when samples were subjected to 
temperature variations and diluted in solvents from 
different manufacturers. The satisfactory recovery of 
LPSF/AC-04 from liposomes (>99%) stored at different 
temperatures confirmed that the molar absorptivity of 
LPSF/AC04 is not dependent on temperature.
Application of the method: determination of 
LPSF/AC04 in inclusion complex and liposomes
The encapsulation efficiencies of LPSF/AC04 
and LPSF/AC04:HP-β-CD in liposomes were 99.02 
± 1.56% and 93.57 ± 0.37%, respectively. In the 
literature, the quantification of hydrophobic molecules in 
inclusion complexes and liposomes have been performed 
successfully using the proposed spectrophotometry 
method (Siqueira-Moura et al., 2008; Cavalcanti et al., 
2012; Lapenda et al., 2012).
The high encapsulation efficiency of LPSF/AC04 
and LPSF/AC04:HP-β-CD from liposomes indicated the 
effectiveness of the proposed method in the quantification 
of LPSF/AC04.
CONCLUSION
The proposed spectrophotometric analytical method 
for determination of LPSF/AC04 proved simple, rapid, 
accurate, precise and low-cost. The method was applied to 
quantify the LPSF/AC04 in inclusion complex as well in 
liposomes and can therefore be used for routine analysis.
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